Supplemental figure 1. Systemic DMOG treatment during chronic CS exposure does not affect CS-induced pulmonary inflammation and damage in experimental COPD.

Mice were exposed to CS for 8 weeks to induce experimental COPD and were treated systemically with DMOG throughout. (a-d) Enumeration of BALF leukocytes revealed no significant effect of DMOG on the accumulation of leukocytes in the airways of CS-exposed groups. (e) mRNA expression of key inflammatory and pathogenic mediators MCP1, CXCL1 and MMP12 was not altered by DMOG treatment. (f) DMOG treatment did not prevent CS-induced alveolar enlargement. n = 4-6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.